Giants of Cancer Care® Program Inductees

Lymphoma

Fernando Cabanillas, MD

Auxilio Centro

Cabanillas is chairman of Centro de Cancer Auxilio Mutuo Hospital Español Auxilio Mutuo de Puerto Rico and a professor of medicine at University of Puerto Rico School of Medicine.
Cabanillas was among the first investigators to identify salvage therapies for patients with relapsed lymphomas and curative regimens for those with indolent non-Hodgkin lymphomas; these treatments included ifosfamide-based combinations.
He was the lead author for a study showing that MIME (methyl-GAG plus ifosfamide, methotrexate, and etoposide) extended relapse-free and median overall survival for patients with recurrent/refractory lymphoma.
He was also a coauthor for studies showing that adding rituximab to R-hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) improved outcomes for adults with Burkitt-type lymphoma and B-cell acute lymphoblastic leukemia.
In 2019, Cabanillas published data showing that gemcitabine, rituximab (Rituxan), and oxaliplatin followed by lenalidomide (Revlimid; GROC-Rev) was effective as a salvage regimen for patients with relapsed/refractory non-Hodgkin lymphoma.

Home

)

SUPPORTED BY